^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BI 1361849
i
Other names: BI 1361849, CV-9202, CV9202, CV 9202
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CureVac
Drug class:
Immunostimulant
Related drugs:
over2years
Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
P1/2, N=59, Completed, Ludwig Institute for Cancer Research | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2021
Clinical • Trial completion • Trial completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • BI 1361849
3years
Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
P1/2, N=56, Active, not recruiting, Ludwig Institute for Cancer Research | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Oct 2021
Clinical • Enrollment closed • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • BI 1361849 • self-amplifying RNA cancer vaccine
4years
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. (PubMed, J Immunother Cancer)
The results support further investigation of mRNA-based immunotherapy in NSCLC including combinations with immune checkpoint inhibitors.
Clinical • P1 data • Journal
|
MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5)
|
EGFR mutation
|
pemetrexed • BI 1361849
Share via
